Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

Phase 1/2 Recruiting 96 enrolled The Netherlands Cancer Institute

Non-randomizedSequentialOpen-labelTreatment

Summary

This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.

Timeline

Start: 2024-03-08
Primary completion: 2029-07
Completion: 2034-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ipilimumab	Monoclonal antibody	0.5 mg	Intramuscular
Subject	Ipilimumab	Monoclonal antibody	10 mg	Intramuscular
Subject	Nivolumab	Monoclonal antibody	1 mg	Intramuscular
Subject	Nivolumab	Monoclonal antibody	20 mg	Intramuscular
Subject	Nivolumab	Monoclonal antibody	240 mg	Intramuscular

Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

Summary

Timeline

Drugs

Indications